NASDAQ:JAZZ Jazz Pharmaceuticals Q3 2026 Earnings Date & Estimates $214.00 -0.65 (-0.30%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$214.11 +0.11 (+0.05%) As of 10/23/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jazz Pharmaceuticals is estimated to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 2, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Jazz Pharmaceuticals in Q3 2026Jazz Pharmaceuticals is expected to post earnings of $6.26 per share on revenue of $1.21 billion. Jazz Pharmaceuticals last reported on August 3, 2026, posting $5.71 per share and missing the $6.18 consensus estimate. Jazz Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS$6.26Expected Revenue$1.21 billionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS$5.71 (Missed by -$0.47)Last Quarter Revenue$1.21 billionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Jazz Pharmaceuticals Q3 2026 Earnings FAQ When does Jazz Pharmaceuticals report Q3 2026 earnings? Jazz Pharmaceuticals (NASDAQ:JAZZ) is estimated to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Jazz Pharmaceuticals' Q3 2026 earnings call? Jazz Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Jazz Pharmaceuticals? Analysts expect Jazz Pharmaceuticals to post earnings of $6.26 per share for Q3 2026. How much revenue is Jazz Pharmaceuticals expected to report? The consensus revenue estimate for Jazz Pharmaceuticals is $1.21 billion for Q3 2026. Jazz Pharmaceuticals Earnings HeadlinesJazz Pharmaceuticals Reports Positive Phase 3 Results For Ziihera CombinationOctober 23 at 2:43 PM | rttnews.comJazz Pharmaceuticals' Ziihera Shows 3-Year Survival Benefit in Gastroesophageal CancerOctober 23 at 2:43 PM | finance.yahoo.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 25 at 1:00 AM | Crypto 101 Media (Ad)Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026October 23 at 10:15 AM | prnewswire.comJazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026October 19, 2026 | prnewswire.comAditxt (NASDAQ:ADTX) versus Jazz Pharmaceuticals (NASDAQ:JAZZ) Critical ContrastOctober 17, 2026 | americanbankingnews.comSee More Jazz Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jazz Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jazz Pharmaceuticals and other key companies, straight to your email. Email Address About Jazz PharmaceuticalsJazz Pharmaceuticals (NASDAQ:JAZZ) is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships. Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy. These medicines are supported by patient services, education and adherence programs. In oncology and hematology, Jazz markets products including Rylaze, Zepzelca and Vyxeos for select cancers and related conditions. The company was founded in 2003 and is headquartered in Dublin, Ireland, with substantial operations in the United States. Jazz was co-founded by Bruce Cozadd, who has served as a longtime senior leader of the company.View Jazz Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineNewmont’s Record Quarter Shows Why Gold’s Floor Is the Real StoryLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
